PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. - Wikidata - wikimedia - TriplyDB

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.

http://www.wikidata.org/entity/Q33409825

about

Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?Novel agents in the treatment of multiple myeloma: a review about the future Clinical use and applications of histone deacetylase inhibitors in multiple myeloma Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor DNA Methylation and Chromatin Remodeling: The Blueprint of Cancer Epigenetics Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity Panobinostat for the treatment of multiple myeloma: the evidence to date New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)Innovative agents in multiple myeloma The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective Recent advances in understanding multiple myeloma The role of maintenance therapy in multiple myeloma Clinical use of proteasome inhibitors in the treatment of multiple myeloma Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy Trial Watch: Proteasomal inhibitors for anticancer therapy Utilization of translational bioinformatics to identify novel biomarkers of bortezomib resistance in multiple myeloma Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer.A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma.Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors Efficacy and Safety of Panobinostat in Relapsed or/and Refractory Multiple Myeloma: Meta Analyses of Clinical Trials and Systematic Review.A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens.Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma.Deacetylase inhibitors: an advance in myeloma therapy?Update on the optimal use of bortezomib in the treatment of multiple myeloma A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma.Clinical Pharmacokinetics and Pharmacodynamics of Panobinostat.Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice.Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells.The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma.

P2860

Q26739689-A27B4EB5-A3BA-4E85-8289-A642189C90D5 Q26740359-1FE44E02-86DD-4CBC-BC24-E471F3EDF148 Q26745924-C42933F3-E956-4451-BE57-4712D7ABAA20 Q26745930-832226A0-8D99-43FF-9971-9CA4A8190131 Q26747768-558C4D8F-D4CE-4740-B0D0-3E49B6DFC00A Q26749421-8EB00DA0-D0FD-4441-BADC-3ACFFC93FED2 Q26768653-343FD732-1A5E-4291-806D-E97F6248EBEB Q26771331-87C52F08-C32E-43D1-B65A-4B3C9C9ACCE7 Q26778674-AC94E386-AE31-4B2A-BECB-D26C7CDC9C51 Q27004421-6806CC5C-7BE0-4755-BE5D-13ACDB5883BD Q27022493-B8E7A1CD-B23E-42D6-8A26-15DC5DD2CE9D Q28069789-E42AB30A-2DDA-4724-8968-0957ADABEC05 Q28070331-4CCDFB87-AB45-4670-AD70-69BE575E72D9 Q28071644-C987A8D1-4DEC-48C5-AF33-53E00F721595 Q28080999-31E713EE-A83F-473C-9A5F-B1B52742B8C1 Q28082536-F141B537-D10F-43C9-8656-5641C2C72C60 Q28082910-903FF07B-2AB8-4110-B19C-8A5206B74771 Q28544663-675DEB78-DBA0-4AE0-B413-F04C827211A1 Q30802505-F6F5661E-101A-4906-A3C3-016591A6C30D Q33410898-882A3F24-D1FC-4B70-98EF-458C794824B6 Q33410997-E438D1FE-1C9A-4681-8101-7E845BBEA02B Q33418389-57C3A28C-B5CA-4F3A-9C7B-A7A42F66A73B Q33423168-779E9A0C-B7B1-465A-9091-A5081FDC2CA7 Q33428098-66E44D4D-B241-4943-8E91-DF15ED5631C6 Q33429115-587EFE37-E216-46C0-BE6C-3B4292221293 Q33431175-0B234B07-B14C-4338-9CFF-B0D9EFAEEBAB Q33432714-FAA68665-0FD3-4F72-BDE9-34CA2DBF2426 Q33432845-E7D9E77E-A1A4-4E97-97A7-29C55B174B90 Q33436890-3A2974DB-E005-46DA-9AFC-56CF73A632F1 Q33437811-29BD1796-CDD3-42CD-A910-5A7CE07B5AF0 Q33438321-700C4F7A-61CE-4987-A2D2-A3F61BC358C5 Q33440007-B1EDD095-F55F-446B-895B-E8701E04E1E2 Q33442755-89818E3F-A600-4204-BBA7-04CBB9CCEC48 Q33443179-F50C60E1-A6A5-4391-B101-6652ED41BDC0 Q33443417-7E1951CD-3E09-489C-A41D-92606A88521B Q33983255-0C9A7822-AD41-4A9D-B84A-4B9B7D51771B Q34127846-0D7B6F27-5751-4357-8CC6-44F48A6A8D2B Q34218976-B7CFB36A-1B55-4EB4-96C6-7832302A12A7 Q34372977-3F332A8D-0816-4EEC-AB95-496E5A4F8FE3 Q34602263-0B98B152-BAB3-4AAE-81FC-44B27F8311DC

P2860

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.

http://www.wikidata.org/entity/Q33409825

description

2013 nî lūn-bûn

@nan

2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

PANORAMA 2: panobinostat in co ...... bortezomib-refractory myeloma.

@ast

PANORAMA 2: panobinostat in co ...... bortezomib-refractory myeloma.

@en

type

label

PANORAMA 2: panobinostat in co ...... bortezomib-refractory myeloma.

@ast

PANORAMA 2: panobinostat in co ...... bortezomib-refractory myeloma.

@en

prefLabel

PANORAMA 2: panobinostat in co ...... bortezomib-refractory myeloma.

@ast

PANORAMA 2: panobinostat in co ...... bortezomib-refractory myeloma.

@en

P1433

Q33409825-A6B383A0-A987-4531-82C7-578EB71CB2D6

P1476

Q33409825-854C5D19-6E87-4B86-B9EF-9C94935051C6

P2093

Q33409825-399E2A8F-DBEF-4B1B-A0C1-509ADCA3CC66

Q33409825-3F1AEE65-2B97-4492-8ABA-A8C9C7695A48

Q33409825-617E462A-BBE5-4C5C-ABD0-6064989C8575

Q33409825-76E8FCC6-534C-4148-9DD3-902FE0707AE3

Q33409825-85B4D4A6-00D5-4B05-9C01-D7B386E55C04

Q33409825-B23294AC-7050-4560-B3E5-D4A3793D5DC2

Q33409825-C7A29382-362E-416F-A06D-092EF0A1B065

Q33409825-D086DD73-BC74-47A5-B1CB-64153B0735C8

Q33409825-D72417B8-7D7A-48C6-BA96-CD4BE897373F

P304

Q33409825-FF7F17A6-291C-48EB-A2C9-929B9A12E102

P31

Q33409825-DAA679FF-E2C1-4702-9CC6-BF61663D99D4

P356

Q33409825-D68CBDF4-72E7-4962-97E2-2E2EB2BD6C99

P407

Q33409825-64D333A7-6CE1-4B93-8ECF-C2B2977B4613

P433

Q33409825-0097E871-D345-4974-8A8B-C279F64BED28

P478

Q33409825-6D8883C8-565B-49EC-8C1D-8B5DA20C3EBA

P50

Q33409825-03379CDD-7E68-41E3-959E-3EB860F69A76

Q33409825-7758BAFA-82EA-4F00-8A8E-DD7ABC476E97

P577

Q33409825-B94C9A23-5B0B-4EAE-B24C-8A3851A9E7E7

P5875

Q33409825-E6AF48FB-E011-4DAC-A522-52158A8359C7

P698

Q33409825-DC60E332-CFBD-4730-A848-2458D32FF29E

P921

Q33409825-34BADF1E-7D53-461B-B190-31153EA7299F

P356

BLOOD-2013-01-481325

P1433

P1476

PANORAMA 2: panobinostat in co ...... bortezomib-refractory myeloma.

@en

P2093

Carole S Paley

http://www.w3.org/2001/XMLSchema#string

Cristina Gasparetto

http://www.w3.org/2001/XMLSchema#string

Donna M Weber

http://www.w3.org/2001/XMLSchema#string

Mahmudul Khan

http://www.w3.org/2001/XMLSchema#string

Melissa Alsina

http://www.w3.org/2001/XMLSchema#string

Michael S Ondovik

http://www.w3.org/2001/XMLSchema#string

Robert L Schlossman

http://www.w3.org/2001/XMLSchema#string

Steven E Coutre

http://www.w3.org/2001/XMLSchema#string

Sutapa Mukhopadhyay

http://www.w3.org/2001/XMLSchema#string

P304

2331-2337

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2013-01-481325

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

122

http://www.w3.org/2001/XMLSchema#string

P50

Paul G Richardson

P577

2013-08-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

255959074

http://www.w3.org/2001/XMLSchema#string

P698

23950178

http://www.w3.org/2001/XMLSchema#string

P921